Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...

Hims & Hers Health, Inc. (HIMS) announced on Wednesday that it will expand to Canada next year with its weight loss program, ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Novo Nordisk A/S (NYSE:NVO) is one of the 10 best defensive stocks to buy in a volatile market. On July 7, the company ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

The country’s Medicines and Healthcare products Regulatory Agency’s Yellow Card scheme, the UK’s official system for ...

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...

Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...

Experts are warning anyone experiencing GLP-1 drug side effects to report them after launching an investigation into their safety.